Provides concise practical advice for dermatologists
Includes numerous clinical tips and tricks to make therapeutic management more approachable
Features straightforward references to commonly used medications in dermatology
This practical manual provides a real-world educationally focused resource. It enables the reader to gain a good understanding of a range of skin diseases, their differential diagnosis and various medical and/or surgical treatment options. Topics covered include general dermatology, oncodermatology, drugs, phototherapy, pigmentary disorders, skin of color, inpatient dermatology and pediatric dermatology. Emphasis is placed on concise, practical points that one can use in clinic, with informative pearls to reinforce the key messages in each chapter.
Practical Guide to Dermatology: The Henry Ford Manual systematically describes a broad range of practical concepts, diagnostic and treatment techniques involving various dermatological disciplines. It represents a valuable reference guide for practising and trainee dermatologists alike.
Author(s): Henry W. Lim, Laurie L. Kohen, Samantha L. Schneider, Danielle Yeager
Publisher: Springer
Year: 2019
Language: English
Pages: 310
Tags: Dermatology, Skin
Preface......Page 5
Contents......Page 6
Bullous Pemphigoid......Page 8
Dermatomyositis......Page 10
Lupus Erythematosus......Page 12
Discoid Lupus Erythematosus......Page 14
Subacute Cutaneous Lupus......Page 15
Pemphigus Vulgaris......Page 16
Psoriasis, Cutaneous......Page 17
Pyoderma Gangrenosum......Page 21
Morphea......Page 22
Systemic Sclerosis......Page 24
References......Page 26
Atopic Dermatitis (AD)......Page 29
Infantile Hemangiomas (IH)......Page 34
Molluscum Contagiosum: Pediatric Specific Pearls......Page 37
Morphea: Pediatric Specific Pearls......Page 39
Psoriasis: Pediatric Specific Pearls......Page 41
Tinea Capitis......Page 43
Tinea Corporis......Page 45
Nevus Sebaceous/Sebaceus: Pediatric Specific Pearls......Page 47
Verruca: Pediatric Specific Pearls......Page 48
Neonatal Concerns [139]......Page 50
References......Page 52
Anticoagulants Prior to Surgery [1–5]......Page 60
Antiseptics [6–9]......Page 61
Infiltrative Anesthesia [7–11]......Page 62
Topical Anesthesia [10, 12]......Page 64
Surgery Site Infection [2, 7, 14]......Page 65
Surgical Anatomy [7, 8, 14, 15]......Page 67
Excisions [16]......Page 71
Wound Repair [15, 17]......Page 72
Suture Characteristics [7, 15]......Page 75
Flap Basics [7, 15]......Page 77
Post-operative Complications [1–3, 15, 19]......Page 78
References......Page 79
Actinic Keratosis [1–8]......Page 81
SCC in Situ [9–15]......Page 82
Basal Cell Carcinoma [16–20]......Page 83
Squamous Cell Carcinoma [17, 21, 22]......Page 85
Melanoma......Page 88
Merkel Cell Carcinoma [58]......Page 94
Mycosis Fungoides......Page 96
Dermatofibrosarcoma Protuberans......Page 99
Quick Reference for Recommended Surgical Margins of Common Lesions......Page 100
AAD 2012 Mohs Appropriate Use Criteria [87]......Page 101
Mohs Appropriate Use Criteria Treatment Areas......Page 102
References......Page 104
Neuromodulators......Page 109
Fillers......Page 111
Chemical Peels......Page 113
Plasma-Rich Platelet Injections......Page 116
Sclerotherapy......Page 117
Body Contouring......Page 118
Lasers......Page 120
References......Page 123
Biopsy Technique [1, 2]......Page 125
Immunodermatopathology......Page 128
Ancillary Molecular Testing in Dermatopathology......Page 129
What’s the Differential Diagnosis If Your Patient’s Biopsy Shows…......Page 131
References......Page 133
Acne Keloidalis Nuchae (AKN) [1]......Page 134
Alopecia Areata [2–4]......Page 135
Androgenetic Alopecia [5–7]......Page 137
Central Centrifugal Cicatricial Alopecia (CCCA) [8]......Page 138
Lichen Planopilaris [9, 10]......Page 139
Telogen Effluvium [11]......Page 140
Hidradenitis Suppurativa [13–18]......Page 141
Pseudofolliculitis Barbae [20]......Page 144
References......Page 145
Calciphylaxis (aka calcific uremic arteriolopathy) [1]......Page 147
Cutaneous Metastases [2]......Page 148
Drug Eruptions......Page 149
Exanthematous Drug Eruption [3]......Page 150
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Drug-Induced Hypersensitivity Syndrome (DIHS) [4, 5]......Page 151
Cutaneous Small Vessel Vasculitis (CSVV) [3]......Page 152
Acute Generalized Exanthematous Pustulosis (AGEP) [6]......Page 154
Acute Febrile Neutrophilic Dermatosis (Sweet Syndrome) [3]......Page 155
Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [7, 8]......Page 156
Erythema Multiforme (EM) [9]......Page 159
Graft Versus Host Disease [10, 11]......Page 160
Deep Fungal Infections......Page 161
Herpes Virus Infections [12–14]......Page 162
Ulcers [15–17]......Page 165
Vasculitis [18]......Page 166
References......Page 168
Phototherapy......Page 169
Individual Phototherapy Modalities......Page 170
NB-UVB (Home Phototherapy) [4]......Page 172
PUVA......Page 173
UVA-1......Page 175
Photodynamic Therapy (PDT)......Page 176
References......Page 177
Antimalarials [1, 2]......Page 178
Azathioprine (Imuran) [1, 2]......Page 180
Corticosteroids (CS) [1, 2]......Page 181
Cyclosporine (CsA) [1, 2]......Page 182
Dapsone [1, 2]......Page 184
Methotrexate (MTX) [1, 2]......Page 185
Mycophenolate Mofetil (Cellcept, MMF) [1, 2]......Page 187
Systemic Retinoids [1, 2]......Page 189
Tumor Necrosis Factor (TNF) Inhibitors [1, 2]......Page 194
Interleukin 12/23 Inhibitor [1, 2]......Page 197
Interleukin 23 Inhibitors [1, 2]......Page 198
Interleukin 17 Inhibitors [1, 2, 52]......Page 199
JAK Inhibitors [1, 2]......Page 200
Apremilast (Otezla) [2]......Page 202
Antiandrogens and Androgen Inhibitors [1, 2]......Page 203
Colchicine [1, 2]......Page 205
IVIg [1, 2]......Page 206
Naltrexone [68]......Page 207
Nicotinamide (Vitamin B3) [69]......Page 208
Rituximab [1, 2]......Page 209
References......Page 210
Ashy Dermatosis/Erythema Dyschromicum Perstans (EDP) [1, 2] Lichen Planus Pigmentosus (LPP) [1, 3]......Page 214
Melasma [1, 2]......Page 215
Post-inflammatory Hyperpigmentation [1, 2]......Page 217
Vitiligo......Page 218
Photoprotection [1, 2, 45]......Page 220
References......Page 221
Acanthosis Nigricans [1]......Page 224
Acne Vulgaris [6]......Page 225
Atopic Dermatitis, Adult [10–12]......Page 228
Brittle Nails [15] (Onychorrhexis)......Page 230
Chronic Urticaria [17, 18]......Page 231
Solar Urticaria [28, 29]......Page 232
Allergic Contact Dermatitis [30]......Page 233
Irritant Contact Dermatitis......Page 235
Chronic Actinic Dermatitis (CAD) [32]......Page 236
Dissecting Cellulitis [33]......Page 237
Drug-Induced Photosensitivity [35, 36]......Page 238
Granuloma Annulare [37]......Page 239
Hirsutism [38, 39]......Page 240
Hyperhidrosis [40–42]......Page 241
Keratosis Pilaris [43]......Page 242
Lichen Planus [44, 45]......Page 243
Lichen Sclerosis et Atrophicus [53]......Page 245
Periorificial Dermatitis [56]......Page 246
Polymorphous Light Eruption (PMLE) [57, 58]......Page 247
Primary Pruritus [61]......Page 249
Porphyria Cutanea Tarda [65]......Page 250
Pseudoporphyria [65, 66]......Page 251
Rosacea [69, 70]......Page 252
Sarcoidosis [71]......Page 253
References......Page 254
Cellulitis [1]......Page 258
Erythrasma......Page 260
Genital Warts (Condyloma Acuminatum)......Page 261
Gram Negative Toe Web Infection [7, 11]......Page 262
Herpes Simplex (HSV) [6, 12–14]......Page 263
Herpes Zoster (VZV) [6, 15]......Page 265
Impetigo [19]......Page 267
Intertrigo [6, 21]......Page 268
Molluscum Contagiosum [6, 22, 23]......Page 269
Paronychia [6, 7]......Page 271
Onychomycosis (Tinea Unguium) [27–30]......Page 272
Tinea Capitis [6, 34, 35]......Page 274
Tinea Corporis/Cruris/Pedis......Page 275
Tinea Versicolor (Pityriasis Versicolor) [6, 40]......Page 276
Pediculosis Capitis [41, 42]......Page 277
Pediculosis Corporis [6, 43]......Page 279
Pediculosis Pubis [6, 44, 45]......Page 280
Perleche [46–48]......Page 281
Scabies [49, 50]......Page 283
Syphilis [45, 52, 53]......Page 284
Varicella (See Herpes Zoster)......Page 286
References......Page 287
Cytotoxic Chemotherapies......Page 290
Epidermal Growth Factor Receptor (EGFR) Inhibitors [75] [76, 77] [78–81] [82–85] [86] [87] [83, 88] [76, 77, 89–91] [92]......Page 294
Multitargeted Small Molecule Tyrosine Kinase Inhibitors [93] [94, 95] [96] [97, 98] [99] [100] [101–107] [108–110] [111, 112] [113, 114] [32] [115] [116, 117] [115, 116]......Page 295
BRAF Inhibitors [128] [129] [130–135] [130, 136] [137] [129–132] [130–132, 138] [129] [130, 131, 139] [140, 141] [142–144] [132–135] [145, 146] [129–132] [129–132, 147] [148]......Page 296
Targeted therapies (hematologic malignancies)......Page 297
Checkpoint Inhibitors [152] [153] [154] [155] [153, 156] [157, 158] [159] [160]......Page 298
References......Page 299
Index......Page 308
